Bifogade filer
Kurs
-2,47%
Likviditet
1,13 MSEK
Prenumeration
Kalender
Tid* | ||
2025-05-09 | N/A | Årsstämma |
2025-02-13 | 08:00 | Bokslutskommuniké 2024 |
2024-11-08 | - | Kvartalsrapport 2024-Q3 |
2024-08-23 | - | Kvartalsrapport 2024-Q2 |
2024-06-03 | - | Split IMMU 20:1 |
2024-05-20 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
2024-05-17 | - | Årsstämma |
2024-05-17 | - | Kvartalsrapport 2024-Q1 |
2024-02-14 | - | Bokslutskommuniké 2023 |
2023-12-13 | - | Extra Bolagsstämma 2023 |
2023-11-09 | - | Kvartalsrapport 2023-Q3 |
2023-08-29 | - | Kvartalsrapport 2023-Q2 |
2023-05-15 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
2023-05-12 | - | Årsstämma |
2023-05-12 | - | Kvartalsrapport 2023-Q1 |
2023-02-17 | - | Bokslutskommuniké 2022 |
2022-11-18 | - | Extra Bolagsstämma 2022 |
2022-11-11 | - | Kvartalsrapport 2022-Q3 |
2022-08-26 | - | Kvartalsrapport 2022-Q2 |
2022-05-11 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
2022-05-10 | - | Årsstämma |
2022-05-10 | - | Kvartalsrapport 2022-Q1 |
2022-02-17 | - | Bokslutskommuniké 2021 |
2021-10-28 | - | Kvartalsrapport 2021-Q3 |
2021-08-26 | - | Kvartalsrapport 2021-Q2 |
2021-05-05 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
2021-05-04 | - | Årsstämma |
2021-05-04 | - | Kvartalsrapport 2021-Q1 |
2021-02-18 | - | Bokslutskommuniké 2020 |
2021-01-22 | - | Extra Bolagsstämma 2021 |
2020-12-18 | - | Extra Bolagsstämma 2020 |
2020-11-05 | - | Kvartalsrapport 2020-Q3 |
2020-08-27 | - | Kvartalsrapport 2020-Q2 |
2020-04-29 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
2020-04-28 | - | Årsstämma |
2020-04-28 | - | Kvartalsrapport 2020-Q1 |
2020-02-18 | - | Bokslutskommuniké 2019 |
2019-11-06 | - | Kvartalsrapport 2019-Q3 |
2019-08-20 | - | Kvartalsrapport 2019-Q2 |
2019-04-26 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
2019-04-25 | - | Årsstämma |
2019-04-25 | - | Kvartalsrapport 2019-Q1 |
2019-02-15 | - | Bokslutskommuniké 2018 |
2018-11-07 | - | Kvartalsrapport 2018-Q3 |
2018-08-17 | - | Kvartalsrapport 2018-Q2 |
2018-05-04 | - | Kvartalsrapport 2018-Q1 |
2018-04-26 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
2018-04-25 | - | Årsstämma |
2018-02-16 | - | Bokslutskommuniké 2017 |
2017-12-04 | - | Extra Bolagsstämma 2017 |
2017-11-17 | - | Kvartalsrapport 2017-Q3 |
2017-08-18 | - | Kvartalsrapport 2017-Q2 |
2017-05-19 | - | Kvartalsrapport 2017-Q1 |
2017-04-27 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
2017-04-26 | - | Årsstämma |
2017-02-17 | - | Bokslutskommuniké 2016 |
2016-05-20 | - | Kvartalsrapport 2016-Q3 |
2016-02-19 | - | Kvartalsrapport 2016-Q2 |
2015-12-03 | - | Årsstämma |
2015-09-18 | - | Bokslutskommuniké 2015 |
2015-05-21 | - | Kvartalsrapport 2015-Q3 |
2015-02-20 | - | Kvartalsrapport 2015-Q2 |
2014-12-04 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
2014-12-03 | - | Årsstämma |
2014-11-18 | - | Kvartalsrapport 2015-Q1 |
2014-09-17 | - | Bokslutskommuniké 2014 |
2014-05-07 | - | Kvartalsrapport 2014-Q3 |
2014-02-18 | - | Kvartalsrapport 2014-Q2 |
2013-12-04 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
2013-12-03 | - | Årsstämma |
2013-12-03 | - | Kvartalsrapport 2014-Q1 |
2013-09-10 | - | Bokslutskommuniké 2013 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Press release
Stockholm, Sweden, June 3, 2024
Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, announces that it will participate in the following upcoming industry conferences in June:
BIO International Convention
San Diego, USA, June 3-6, 2024
Mendus Business Development will attend for industry meetings.
BIO International Convention | June 3-6, 2024 | San Diego
European Hematology Association conference 2024
Madrid, Spain, June 13-16, 2024
Mendus will present data from the ADVANCE II Phase 2 trial in acute myeloid leukemia at the European Hematology Association conference (EHA), the leading European hematology conference. Abstracts are available on the conference website.
Events | EHA Library by European Hematology Association (EHA) (ehaweb.org)
ESMO Gynaecological Cancers Congress 2024
Florence, Italy, June 20-22, 2024
Mendus will present data from the ALISON Phase 1 trial in ovarian cancer at the ESMO Gynaecological Cancers Congress. Abstracts will be published on the conference website on June 17.
ESMO Gynaecological Cancers Congress 2024
For more information, please contact:
Erik Manting
Chief Executive Officer
E-mail: ir@mendus.com
About Mendus AB (publ)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. https://www.mendus.com/
Attachments
240603 Mendus Conferences June ENG